leadf
logo-loader
viewCreso Pharma Ltd

Creso Pharma banks A$320,000 after delivering second shipment of cannaQIX® to Pharma Dynamics in South Africa

Delivery of the second purchase order follows the company’s successful launch into the South African market in collaboration with Pharma Dynamics. 

Creso Pharma Ltd - Creso Pharma banks in A$320,000 after delivering second shipment of cannaQIX® to Pharma Dynamics in South Africa
It believes there will be more purchase orders from this region in a sustainable way

Creso Pharma Ltd (ASX:CPH) (FRA:1X8) (OTCMKTS:COPHF) has completed all required importing and exporting procedures and successfully delivered the second shipment of cannaQIX® products to Lupin International Ltd’s (NYSE:LUPIN) subsidiary, Pharma Dynamics South Africa. 

The delivery of the second purchase order valued CHF220,000 (around A$320,000) follows the company’s successful launch into the South African market in collaboration with Pharma Dynamics. 

Pharma Dynamics launched the cannaQIX® regular products during the second quarter of 2020 and is marketing it under the ‘Cannamics’ brand. 

cannaQIX® is Creso Pharma’s range of cannabidiol (CBD) hemp oil-based nutraceuticals, containing a broad spectrum of organic hemp oil extracts with CBD to improve management of stress and support mental and nervous functions. 

Looking forward to further growth

Creso Pharma commercial director Jorge Wernli, said: “We are excited about the completion of this second-order from Pharma Dynamics, which has underpinned a very successful launch of cannaQIX® under the Cannamics brand in South Africa.

“cannaQIX® has been developed using Good Manufacturing Practice standards and is standardised and user-friendly.

Strength and formulation allow for precise dosage control and the lozenge form is more palatable than many other oils on the current market.

“We have no doubt that it will continue to be well received by consumers in South Africa.

“We are very proud of having accomplished this delivery in spite of the current restrictions in place, mainly due to the COVID situation.

“We are looking forward to further growth throughout South Africa and other territories together with Pharma Dynamics.”

Recurring revenue model

Pharma Dynamics distributes Creso Pharma’s hemp-based products across South Africa, with plans to extend the distribution to Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda

Creso Pharma is confident that additional opportunities will materialise in Africa in the coming months.

It continues to work with Pharma Dynamics to establish a broader footprint in the region and anticipates purchase orders to grow in size and volume.

Creso Pharma is extremely pleased with the swift timing of the second purchase order and delivery, demonstrating a healthy relationship and positive patient response.

The company believes there will be more purchase orders from this region in a sustainable way.

This underpins Creso’s current global growth trajectory and its entry into new markets towards a recurring revenue model.

New exciting opportunities

As of December 31, 2020, Creso Pharma retained a healthy cash balance of more than A$6 million.

Since that date, the company has received an additional A$1.7 million following the exercise of options, giving Creso a robust bank balance to cater to the group’s current operations, and fund the expansion into new markets.

The current sales and revenue announced is very encouraging and this robust bank balance further demonstrates the group’s financial foundation to continue to win market share as well as to be in a position to easily capitalise any potential further international growth opportunities.

There are a number of new, exciting opportunities the company is working on which will be announced in due course.

Pharma Dynamics

Lupin International is ranked as the fifth-largest generic pharmaceutical company in South Africa and it provides high-quality generic medicines at affordable prices.

Pharma Dynamics has a growing range of over-the-counter products including medications for cold and flu, allergy, and digestion, as well as immune booster wellness products.

Its products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.

Quick facts: Creso Pharma Ltd

Price: 0.23 AUD

ASX:CPH
Market: ASX
Market Cap: $209.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 12/6/20

3 min read